
Quest Diagnostics (DGX) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
2.7B
Gross Profit
863.0M
32.54%
Operating Income
346.0M
13.05%
Net Income
235.0M
8.86%
EPS (Diluted)
$1.94
Balance Sheet Metrics
Total Assets
15.8B
Total Liabilities
8.8B
Shareholders Equity
7.0B
Debt to Equity
1.24
Cash Flow Metrics
Operating Cash Flow
298.0M
Free Cash Flow
197.0M
Revenue & Profitability Trend
Quest Diagnostics Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 9.9B | 9.3B | 9.9B | 10.8B | 9.4B |
Cost of Goods Sold | 6.6B | 6.2B | 6.4B | 6.6B | 5.8B |
Gross Profit | 3.2B | 3.1B | 3.4B | 4.2B | 3.6B |
Gross Margin % | 32.9% | 33.0% | 34.7% | 39.0% | 38.5% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 1.8B | 1.6B | 1.9B | 1.7B | 1.6B |
Other Operating Expenses | 1.0M | 41.0M | 11.0M | -2.0M | 9.0M |
Total Operating Expenses | 1.8B | 1.7B | 1.9B | 1.7B | 1.6B |
Operating Income | 1.3B | 1.3B | 1.4B | 2.4B | 2.0B |
Operating Margin % | 13.6% | 13.6% | 14.4% | 22.1% | 20.9% |
Non-Operating Items | |||||
Interest Income | 25.0M | 11.0M | 10.0M | 1.0M | 3.0M |
Interest Expense | 226.0M | 163.0M | 148.0M | 152.0M | 166.0M |
Other Non-Operating Income | 30.0M | 20.0M | -55.0M | 369.0M | 76.0M |
Pre-tax Income | 1.2B | 1.1B | 1.2B | 2.6B | 1.9B |
Income Tax | 273.0M | 248.0M | 264.0M | 597.0M | 460.0M |
Effective Tax Rate % | 23.2% | 21.9% | 21.4% | 23.0% | 24.4% |
Net Income | 921.0M | 908.0M | 1.0B | 2.1B | 1.5B |
Net Margin % | 9.3% | 9.8% | 10.3% | 19.3% | 15.9% |
Key Metrics | |||||
EBITDA | 1.9B | 1.7B | 1.8B | 3.2B | 2.4B |
EPS (Basic) | $7.78 | $7.59 | $8.10 | $15.85 | $10.62 |
EPS (Diluted) | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 |
Basic Shares Outstanding | 111000000 | 112000000 | 116000000 | 125000000 | 134000000 |
Diluted Shares Outstanding | 111000000 | 112000000 | 116000000 | 125000000 | 134000000 |
Income Statement Trend
Quest Diagnostics Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 549.0M | 686.0M | 315.0M | 872.0M | 1.2B |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 1.3B | 1.2B | 1.2B | 1.4B | 1.5B |
Inventory | 188.0M | 190.0M | 192.0M | 208.0M | 223.0M |
Other Current Assets | 351.0M | 286.0M | 196.0M | 223.0M | - |
Total Current Assets | 2.4B | 2.4B | 1.9B | 2.7B | 3.1B |
Non-Current Assets | |||||
Property, Plant & Equipment | 651.0M | 602.0M | 585.0M | 597.0M | 604.0M |
Goodwill | 19.5B | 16.6B | 15.5B | 15.4B | 14.9B |
Intangible Assets | 1.8B | 1.2B | 1.1B | 1.2B | 1.2B |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 255.0M | 198.0M | 144.0M | 163.0M | 176.0M |
Total Non-Current Assets | 13.8B | 11.6B | 10.9B | 10.9B | 11.0B |
Total Assets | 16.2B | 14.0B | 12.8B | 13.6B | 14.0B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 287.0M | 378.0M | 324.0M | 357.0M | 446.0M |
Short-term Debt | 937.0M | 585.0M | 247.0M | 269.0M | 296.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 2.2B | 1.8B | 1.6B | 1.8B | 1.8B |
Non-Current Liabilities | |||||
Long-term Debt | 6.2B | 4.9B | 4.5B | 4.5B | 4.5B |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 938.0M | 876.0M | 812.0M | 792.0M | 847.0M |
Total Non-Current Liabilities | 7.1B | 5.8B | 5.3B | 5.3B | 5.4B |
Total Liabilities | 9.3B | 7.6B | 6.8B | 7.0B | 7.1B |
Equity | |||||
Common Stock | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M |
Retained Earnings | 9.4B | 8.8B | 8.3B | 7.6B | 9.3B |
Treasury Stock | 4.9B | 4.8B | 4.7B | 3.5B | 5.4B |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 6.9B | 6.4B | 6.0B | 6.6B | 6.9B |
Key Metrics | |||||
Total Debt | 7.1B | 5.5B | 4.7B | 4.8B | 4.8B |
Working Capital | 223.0M | 557.0M | 347.0M | 988.0M | 1.3B |
Balance Sheet Composition
Quest Diagnostics Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 921.0M | 908.0M | 1.0B | 2.1B | 1.5B |
Depreciation & Amortization | 493.0M | 439.0M | 437.0M | 408.0M | 361.0M |
Stock-Based Compensation | 88.0M | 77.0M | 77.0M | 79.0M | 97.0M |
Working Capital Changes | -217.0M | -143.0M | 150.0M | 107.0M | 0 |
Operating Cash Flow | 1.3B | 1.3B | 1.7B | 2.6B | 2.0B |
Investing Activities | |||||
Capital Expenditures | - | - | - | 3.0M | 3.0M |
Acquisitions | -2.2B | -611.0M | -144.0M | 424.0M | -330.0M |
Investment Purchases | - | - | - | -3.0M | -27.0M |
Investment Sales | - | - | 5.0M | 0 | - |
Investing Cash Flow | -2.1B | -611.0M | -139.0M | 424.0M | -354.0M |
Financing Activities | |||||
Share Repurchases | -151.0M | -275.0M | -1.4B | -2.2B | -325.0M |
Dividends Paid | -331.0M | -314.0M | -305.0M | -309.0M | -297.0M |
Debt Issuance | 1.8B | 2.6B | 0 | 0 | 749.0M |
Debt Repayment | -303.0M | -1.8B | -2.0M | -2.0M | -1.6B |
Financing Cash Flow | 1.0B | 88.0M | -1.9B | -2.7B | -1.5B |
Free Cash Flow | 909.0M | 864.0M | 1.3B | 1.8B | 1.6B |
Net Change in Cash | 201.0M | 750.0M | -248.0M | 318.0M | 151.0M |
Cash Flow Trend
Quest Diagnostics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
21.56
Forward P/E
18.42
Price to Book
2.79
Price to Sales
1.91
PEG Ratio
0.96
Profitability Ratios
Profit Margin
9.03%
Operating Margin
15.10%
Return on Equity
14.26%
Return on Assets
6.34%
Financial Health
Current Ratio
1.09
Debt to Equity
86.90
Beta
0.46
Per Share Data
EPS (TTM)
$8.34
Book Value per Share
$64.54
Revenue per Share
$94.37
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
dgx | 20.1B | 21.56 | 2.79 | 14.26% | 9.03% | 86.90 |
Thermo Fisher | 184.1B | 28.17 | 3.64 | 13.42% | 15.24% | 69.62 |
Danaher | 151.0B | 44.88 | 2.89 | 6.68% | 14.21% | 35.45 |
Idexx Laboratories | 50.9B | 53.10 | 34.98 | 64.87% | 24.41% | 84.81 |
Agilent Technologies | 33.3B | 28.78 | 5.42 | 18.88% | 17.59% | 60.04 |
Iqvia Holdings | 32.7B | 27.94 | 5.66 | 19.79% | 7.88% | 272.12 |
Financial data is updated regularly. All figures are in the company's reporting currency.